Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Rituximab 4Tacrolimus 3fludarabine 2cobomarsen 2Peripheral Blood Stem Cell Transplantation 2Ganciclovir 2Etoposide 2Cyclophosphamide 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine phosphate 1ferric carboxymaltose 1epratuzumab 1denileukin diftitox 1dacetuzumab 1beta-Glucans 1arginine butyrate 1Vorinostat 1Vincristine 1Valganciclovir 1Stem Cell Transplantation 1Sirolimus 1Prednisone 1Oxycodone 1Mycophenolic Acid 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoproliferative Disorders × 10-propargyl-10-deazaaminopterin × Clear all
NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
21 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡